drugset / Trial / NCT00719862

A Study to Evaluate the Safety & Effectiveness of a Nasal Spray to Treat Seasonal Allergies

NCT00719862

Phase 3 Completed 481 enrolled Meda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Purpose of this study is to determine if one allergy medication (0.15% azelastine hydrochloride) is more effective than Placebo alone

Timeline

Start
2007-08
Primary completion
2007-11
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Azelastine Small molecule 0.15 % Intranasal
Comparator Azelastine Small molecule 822 ug Intranasal